Yunxia Sui

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

Désirée van der Heijde, In-Ho Song, Aileen L. Pangan et al. · The Lancet · 2019 · 346 citations · Full text

Medicine, Pharmacotherapy, Rheumatology +2

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial

Désirée van der Heijde, Xenofon Baraliakos, Joachim Sieper et al. · Annals of the Rheumatic Diseases · 2022 · 124 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension

Atul Deodhar, Désirée van der Heijde, Joachim Sieper et al. · Arthritis & Rheumatology · 2021 · 64 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +8

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension

Désirée van der Heijde, Atul Deodhar, Walter P. Maksymowych et al. · RMD Open · 2022 · 49 citations · Full text

Medicine, Pharmacotherapy, Musculoskeletal Medicine +6

Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy

Xiaofeng Zeng, Dongbao Zhao, S. Radominski et al. · International Journal of Rheumatic Diseases · 2021 · 23 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +12